Top

Rheumatology International

Published in:

01-03-2011 | Letter to the Editor

Rituximab and leflunomide for Wegener’s granulomatosis: a long-term follow-up

Authors: J. C. Henes, L. Kanz, I. Koetter

Published in: Rheumatology International | Issue 3/2011

Excerpt

Dear Editor, …

Henes JC, Fritz J, Koch S, Klein R, Horger M, Risler T et al (2007) Rituximab for treatment-resistant extensive Wegener’s granulomatosis—additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 26(10):1711–1715CrossRefPubMed

Smith KG, Jones RB, Burns SM, Jayne DR (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54(9):2970–2982CrossRefPubMed

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D (2006) Long term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45(11):1432–1436CrossRef

Jayne D, Rasmussen N, Andrassy K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44CrossRefPubMed

Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG (1996) The Dutch co-trimoxazole Wegener study group. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. N Engl J Med 335:16–20CrossRefPubMed

Title: Rituximab and leflunomide for Wegener’s granulomatosis: a long-term follow-up
Authors: J. C. Henes
L. Kanz
I. Koetter
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 3/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-010-1462-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Rituximab and leflunomide for Wegener’s granulomatosis: a long-term follow-up

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2011

Diagnosis of a 65-year-old male patient with Takayasu’s arteritis by 18F-FDG PET/CT

Validation of the World Health Organization disability assessment schedule II (WHODAS-II) in patients with osteoarthritis

Cementless total hip arthroplasty in patients with rheumatoid arthritis using a tapered designed titanium hip stem minimum: 10-year results

Which is the dominant factor for perception of rheumatic pain: meteorology or psychology?

Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression

Manual lymphatic drainage in management of edema in a case with CRPS: why the(y) wait?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page